Leica Microsystems, world-leading provider of Total Digital Pathology solutions, and Indica Labs, developing excellence in image analysis for Digital Pathology, today announce the integration of Indica Labs’ advanced image analysis algorithm portfolio into Leica Microsystems digital pathology solution.
Users of the Leica Microsystems Tissue IA product can now source from Indica Labs, a range of image analysis algorithms, providing solutions to many diverse tissue-based quantification applications.
Indica Labs’ image analysis algorithms for molecular assay and morphological feature detection and quantification in whole slide images, coupled with Leica Microsystems’ Tissue IA, provides an easy-to-use solution for complex image analysis problems in Digital Pathology. Leica Microsystems Tissue IA software is a key component of the Total Digital Pathology portfolio and enables the analysis of whole slide images at the touch of a button. The Indica Labs range, including algorithms for neurobiology, toxicological pathology and brightfield ISH, can now be seamlessly integrated with Leica’s Tissue IA, providing a powerful, yet easy-to-use solution for a broad range of targeted applications.
Furthermore, custom image analysis algorithms can be developed by Indica Labs to meet users’ varied and specific requirements, facilitating true flexibility in analysis options.
Donal O’Shea, Head of Digital Pathology in Leica Microsystems says, “Leica Microsystems remains committed to our open and collaborative approach with third party vendors in the digital pathology market. This collaboration with Indica Labs provides an additional choice for our Digital Pathology customers in translational research and biopharma, allowing them to engage with a specialist vendor to seek high end image analysis capability, while leveraging the underlying power of Leica Microsystems’ Digital Pathology solutions.”
Indica Labs’ image analysis solutions are developed with a key focus on the end users’ requirements, providing meaningful output data for publications, reports and studies. With particular focus and experience in the pharmaceutical industry, Indica’s analysis solutions “provide a unique complement to the Leica product line.” remarks Indica CEO, Steven Hashagen. “Together we’ve been able to achieve a truly seamless integration, which will allow Leica users to access Indica’s large portfolio of precision image analysis tools within the familiar Tissue IA workflow.”
While Leica Microsystems will continue to develop and expand its existing range of Digital Pathology image analysis solutions, including Tissue IA and the Ariol system, the integration with Indica Labs give additional options to customers, enabling them to choose the analysis solution that is right for their needs.